December edition of PharmaTimes out now
Holograms in healthcare
These visual projections are coming to a healthcare space near you
Prepare a market pre-launch
Top tips on successfully preparing a drug for market
Takeda aims for best in class
Market access and a greater focus on specialist medicines are key to Takeda UK’s drive to be best in class for employees and customers
Cover story: patients
Practice what you preach
Is pharma walking the walk when it comes to patient centricity?
Dosh for docs
New rules on disclosing pharma payments to doctors are about to come into force. So what can we expect?
Diabetes at a glance
What’s hot in the burgeoning field of diabetes
A clear vision
Instead of finger-pointing and blame, the three major parties should find consensus on how the long-term stability of the NHS can be assured
Fully involving patients in the drug development process will soon be a given
“Things happen when we sit down as equals”
A Parkinson’s disease patient talks of the empowered patient and unmet needs
Click here to see the latest PharmaTimes Magazine
To subscribe go to www.pharmatimes.com/subscribe; digital available from:
Outcomes: a gamechanger for pharma
Patient-recorded outcome measures are likely to become a key part of how healthcare is provided, funded and managed. But is industry ready?
Healthcare Writer Lynne Taylor
The British government’s determination to place health outcomes at the heart of NHS decision-making presents UK-based drugmakers with a unique and potentially huge advantage over their global competitors.
Working in collaboration with the NHS to identify a product’s true value – in other words its value to the patient – has the potential to boost levels of medicines uptake and could also lead to products arriving earlier to market, both in the UK and overseas, a PharmaTimes business meeting was told recently. Leading these potentially game-changing opportunities is the NHS patient-recorded outcome measures programme, which began in 2009.
Innovative drugmakers have included PROMs in their clinical trials for many years, and the data have also long been used in observational studies and population health surveys. “We have decades of experience using these instruments and pharma is way ahead of the game. The fact they are now being measured in healthcare systems changes everything,” Professor Nancy Devlin, research director at the Office of Health Economics told the meeting. Indeed, PROMs are likely to become a key part of how all healthcare is provided, funded and managed, The King’s Fund healthcare policy think-tank has forecast.
So what exactly are PROMs and why should this matter to pharma? You can find out by reading the full article online here
See what's coming up in the March issue [PDF]
Visions 2014 supplement
Creating a balance between
reimbursement and innovation
How to plan early
What more does pharma need to do?
We asked you what the big developments in 2014 will be?
Change is key to opportunity
What to adapt for
Future-proofing the sales team
An example of a new R&D model
Visions in a nutshell
The complete Visions 2014 supplement PDF is available to download
Subscription is free to qualifying UK subscribers
To read articles in full and features in the magazine, why not subscribe
Average circulation Jan - Dec 2013: 23,178